Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Alzheimer's, NHS
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year.
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales, "does not currently demonstrate value" for money.
Pioneering Alzheimer's drug rejected for widespread use in NHS in England
This is the second time a new Alzheimer's treatment has been rejected by the health spending watchdog in a matter of months.
UK's NHS to block Eli Lilly's Alzheimer's drug on Wednesday, Telegraph reports
Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too expensive for NHS patients, the Telegraph reported on Tuesday.
Alzheimer's drug that slows down disease rejected for widespread use on the NHS
People will not be able to access the drug, which slows progression of the disease by four to seven months, on the NHS
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns. Donanemab was on Wednesday approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for people in Britain with mild cognitive impairment, or those in the early stages of Alzheimer ’s disease.
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a type of drug called a monoclonal antibody, which is given by infusion (through a drip in the arm).
UK's medicines regulator approves Lilly's drug for early Alzheimer's
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, the company said on Wednesday. Britain is the third major market where donanemab,
Daily Express
42m
Alzheimer’s £600k wonder drug blocked by NHS over cost despite major breakthrough
The most effective drug against
Alzheimer
's, which can increase a patient's ability to carry out everyday tasks by '40 ...
1h
on MSN
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Linked to E. coli outbreak
Arlington visit records order
Arrested in trafficking case
To close 150 locations
MO court upholds release
Trespassing charge upheld
Lake Erie toxic algae study
Veteran film producer dies
To appear on Rogan podcast
2 US troops injured in raid
FDA approves RSV vaccine
Giant ‘ghost’ fish spotted
DOJ alleges racial bias
GA election rules appeal
FAA finalizes safety rules
Brain stimulation study
Six indicted for fraud in Ohio
Infant mortality increased
SK mulls arms for Ukraine
2025 Medicare changes
Same-day pharmacy delivery
Raises US growth forecast
Target to cut prices
Probing leak of US intel
US semiconductor tax credit
Hospitals' IV fluid shortage
Ordered to hand over assets
Right whale population rises
Reveals 2025 tax brackets
To headline 2 Harris rallies
Feedback